Trial Profile
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Determine the Efficacy, Safety, and Tolerability of AD-4833-536 in the Treatment of Subjects With Type 2 Diabetes and Hypertension.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Jun 2013
Price :
$35
*
At a glance
- Drugs Pioglitazone/azilsartan (Primary) ; Pioglitazone
- Indications Hypertension in diabetes; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 13 Nov 2007 Status changed from recruiting to discontinued. An improvement in pharmaceutical formulation is needed for this combination.
- 04 Nov 2006 New trial record.